Narihito Seki

5.2k total citations · 1 hit paper
134 papers, 3.4k citations indexed

About

Narihito Seki is a scholar working on Urology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Narihito Seki has authored 134 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Urology, 42 papers in Pulmonary and Respiratory Medicine and 31 papers in Rheumatology. Recurrent topics in Narihito Seki's work include Urinary Bladder and Prostate Research (56 papers), Pelvic floor disorders treatments (28 papers) and Prostate Cancer Diagnosis and Treatment (26 papers). Narihito Seki is often cited by papers focused on Urinary Bladder and Prostate Research (56 papers), Pelvic floor disorders treatments (28 papers) and Prostate Cancer Diagnosis and Treatment (26 papers). Narihito Seki collaborates with scholars based in Japan, United States and China. Narihito Seki's co-authors include Seiji Naito, Yukio Homma, Hidehiro Κakizaki, Osamu Yokoyama, Osamu Yamaguchi, Momokazu Gotoh, Masayuki Takeda, Osamu Nishizawa, Masaki Yoshida and Junichi Kodama and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Physiology and Scientific Reports.

In The Last Decade

Narihito Seki

130 papers receiving 3.3k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score

2006 574 citations Yukio Homma, Masaki Yoshida et al. Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Narihito Seki Japan	31	1.9k	1.5k	803	795	654	134	3.4k
Steen Walter Denmark	31	1.4k 0.7×	1.3k 0.9×	770 1.0×	604 0.8×	357 0.5×	125	2.9k
Ettore Mearini Italy	32	923 0.5×	851 0.6×	833 1.0×	206 0.3×	683 1.0×	137	2.6k
Po‐Hui Chiang Taiwan	26	1.1k 0.6×	620 0.4×	625 0.8×	185 0.2×	158 0.2×	126	2.2k
Kazumasa Torimoto Japan	22	767 0.4×	486 0.3×	427 0.5×	248 0.3×	280 0.4×	157	1.9k
Ronald P. Kaufman United States	30	429 0.2×	436 0.3×	1.4k 1.8×	96 0.1×	670 1.0×	78	3.2k
Amirali Salmasi United States	24	367 0.2×	261 0.2×	656 0.8×	48 0.1×	515 0.8×	83	1.9k
Eiji Higashihara Japan	33	130 0.1×	136 0.1×	1.3k 1.6×	140 0.2×	1.6k 2.5×	166	4.2k
Lucía Mercedes Mauro United States	20	155 0.1×	157 0.1×	253 0.3×	156 0.2×	1.4k 2.2×	44	2.7k
Jill T. Norman United Kingdom	34	105 0.1×	128 0.1×	717 0.9×	131 0.2×	1.6k 2.4×	64	3.8k
Francesco Berardinelli Italy	26	184 0.1×	92 0.1×	574 0.7×	85 0.1×	829 1.3×	88	1.9k

Countries citing papers authored by Narihito Seki

Since Specialization

Citations

This map shows the geographic impact of Narihito Seki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narihito Seki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narihito Seki more than expected).

Fields of papers citing papers by Narihito Seki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narihito Seki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narihito Seki. The network helps show where Narihito Seki may publish in the future.

Co-authorship network of co-authors of Narihito Seki

This figure shows the co-authorship network connecting the top 25 collaborators of Narihito Seki. A scholar is included among the top collaborators of Narihito Seki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Narihito Seki. Narihito Seki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Minato, Akinori, Toshihisa Tomoda, Hiroyuki Masaoka, et al.. (2024). Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Clinical Genitourinary Cancer. 22(5). 102148–102148. 3 indexed citations

Nakahara, Yoshiro, Terufumi Kato, Toshihiro Misumi, et al.. (2023). LBA70 OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833). Annals of Oncology. 34. S1313–S1313. 9 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2023). Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study. Anticancer Research. 43(10). 4701–4708. 1 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2022). The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status. OncoTargets and Therapy. Volume 15. 1321–1330. 1 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2022). Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab. Cancer Management and Research. Volume 14. 1641–1651. 6 indexed citations

Minato, Akinori, Takahito Negishi, Naotaka Sakamoto, et al.. (2021). The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab. Cancer Management and Research. Volume 13. 8049–8056. 17 indexed citations

Negishi, Takahito, Naotaka Sakamoto, YooHyun Song, et al.. (2021). Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy. OncoTargets and Therapy. Volume 14. 1981–1988. 9 indexed citations

Negishi, Takahito, Naotaka Sakamoto, Shingo Tamura, et al.. (2021). Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy. In Vivo. 35(5). 2869–2874. 2 indexed citations

Yoshida, Masaki, Hideki Origasa, & Narihito Seki. (2017). Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. LUTS Lower Urinary Tract Symptoms. 9(3). 176–186. 8 indexed citations

10.

Kajioka, Shunichi, et al.. (2012). Functional Role of Muscarinic Receptor Subtypes in Calcium Sensitization and Their Contribution to Rho-kinase and Protein Kinase C Pathways in Contraction of Human Detrusor Smooth Muscle. Urology. 79(5). 1184.e7–1184.e13. 9 indexed citations

11.

Nomura, Hiroyuki, Narihito Seki, Akito Yamaguchi, & Seiji Naito. (2008). Photoselective vaporization of the prostate: Outcome according to the prostate size in a series of 102 Japanese patients. International Journal of Urology. 16(1). 87–90. 8 indexed citations

12.

Seki, Narihito, et al.. (2008). Analysis of the prognostic factors for overactive bladder symptoms following surgical treatment in patients with benign prostatic obstruction. Neurourology and Urodynamics. 28(3). 197–201. 41 indexed citations

13.

Araki, Isao, Masayuki Takeda, Yukio Homma, et al.. (2007). PREDICTIVE FACTORS FOR THE EFFECT OF ALPHA1- ADRENOCEPTOR ANTAGONIST ON SUBJECTIVE AND OBJECTIVE PARAMETERS IN PATIENTS WITH NEUROGENIC LOWER URINARY TRACT DYSFUNCTION: SPECIAL FOCUS ON ALPHA1-D/A ADRENOCEPTOR ANTAGONIST NAFTOPIDIL. 1 indexed citations

14.

Tomoda, Toshihisa, Hai‐Lei Zhu, Atsushi Shibata, et al.. (2007). Effects of flavoxate hydrochloride on voltage-dependent Ba2+ currents in human detrusor myocytes at different experimental temperatures. Naunyn-Schmiedeberg s Archives of Pharmacology. 376(3). 195–203. 3 indexed citations

15.

Kodama, Junichi, Hasengaowa, Tamon Kusumoto, et al.. (2006). Prognostic significance of stromal versican expression in human endometrial cancer. Annals of Oncology. 18(2). 269–274. 56 indexed citations

16.

Yunoki, Takakazu, et al.. (2003). The effects of MCC-134 on the ATP-sensitive K+ channels in pig urethra. European Journal of Pharmacology. 482(1-3). 287–295. 3 indexed citations

17.

Seki, Narihito, et al.. (2001). A Case of Bladder Pheochromocytoma. Urologia Internationalis. 66(1). 57–60. 11 indexed citations

18.

Hashimoto, Ichiro, Junichi Kodama, Narihito Seki, et al.. (2001). Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. British Journal of Cancer. 85(1). 93–97. 110 indexed citations

19.

Hashitani, Hikaru, et al.. (1993). Electrophysiological comparison of the effects of MCI-154 on smooth muscles between mesenteric artery and vein of dogs. General Pharmacology The Vascular System. 24(2). 333–340. 1 indexed citations

20.

Seki, Narihito, et al.. (1988). Alpha and beta adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein.. Journal of Pharmacology and Experimental Therapeutics. 246(3). 1116–1122. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact